Table 2.

Investigational medicinal products used in the FIRE-8 trial during first-line treatment

Study Arm	IMP	Dose	Dosing schedule (day of 28-day cycle)	Administration
A and B	Trifluridine/ tipiracil	35 mg/m2/dose BID	1–5 and 8–12	orally
A	Panitumumab	6 mg/kg body weight	1 and 15	i.v. over 30–60 mina
B	Bevacizumab	5 mg/kg body weight	1 and 15	i.v. over 60 ± 15 minb

IMP Investigational medicinal product, i.v. intravenous infusion, BID twice daily

^afirst administration over 60 min; ^bfirst administration over 90 ± 15 min